1. Comparison of the stability, efficacy and adverse effect profile of the innovator 0.005% latanoprost ophthalmic solution and a novel cyclodextrin-containing formulation;Gonzalez;J Clin Pharmacol.,2007
2. US Department of Health and Human Services Food and Drug Administration Guidance for Industry: (Q1A)R2 Stability Testing of New Drug Substances and Products http://www.fda.gov/cder/guidance/5635fnl.pdf
3. European Medicines Agency International Conference on Harmonisation: Topic Q1A (R2) Stability Testing of New Drug Substances and Products http://www.emea.eu.int/pdfs/human/ich/273699en.pdf
4. Interaction of preservatives with macromolecules: Part I. Natural hydrocolloids;Kurup;Phar Acta Helv,1992
5. Interaction of preservatives with macromolecules: Part II. Cellulose derivatives;Kurup;Phar Acta Helv,1995